Literature DB >> 20978876

Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions.

Motoshi Ichikawa, Akira Hangaishi, Yasuhito Nannya, Mineo Kurokawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20978876     DOI： 10.1007/s12185-010-0711-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  5 in total

1.  Low-dose Gemtuzumab-Ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study.

Authors:  Antonella Poloni; Debora Capelli; Silvia Trappolini; Benedetta Costantini; Mauro Montanari; Guido Gini; Ilaria Scortechini; Giorgia Mancini; Giancarlo Discepoli; Pietro Leoni; Attilio Olivieri
Journal:  Br J Haematol       Date:  2010-04-05       Impact factor: 6.998

2.  Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia.

Authors:  Abdul Rahman El Kinge; Hassan A Hatoum; Rami A Mahfouz; Zaher K Otrock; Elias Jabbour; Hagop Kantarjian; Ali Bazarbachi
Journal:  Leuk Res       Date:  2008-06-20       Impact factor: 3.156

3.  High-dose daunorubicin in older patients with acute myeloid leukemia.

Authors:  Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

4.  Anthracycline dose intensification in acute myeloid leukemia.

Authors:  Hugo F Fernandez; Zhuoxin Sun; Xiaopan Yao; Mark R Litzow; Selina M Luger; Elisabeth M Paietta; Janis Racevskis; Gordon W Dewald; Rhett P Ketterling; John M Bennett; Jacob M Rowe; Hillard M Lazarus; Martin S Tallman
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

5.  Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study.

Authors:  Bob Löwenberg; Joachim Beck; Carlos Graux; Wim van Putten; Harry C Schouten; Leo F Verdonck; Augustin Ferrant; Pieter Sonneveld; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Dimitri Breems; Hilde de Muijnck; Ron Schaafsma; Gregor Verhoef; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gert J Ossenkoppele; Johan Maertens
Journal:  Blood       Date:  2010-01-26       Impact factor: 22.113
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.